Handbook of Targeted Cancer Therapy and Immunotherapy, Second edition

 

Description:

Publisher's Note: Products purchased from 3rd Party sellers are not guaranteed by the Publisher for quality, authenticity, or access to any online entitlements included with the product. A must-have resource for oncologists, researchers, and other cancer care professionals!

 

Table of Contents:

 

Section 1 Targets by Organ Site

Abbreviations

Adrenocortical Carcinoma (ACC)—Mouhammed A. Habra, Aung Naing

Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct)—Milind Javle, Ahmed O. Kaseb, Goldy C. George, Kathrina Marcelo-Lewis, David S. Hong

Bladder Carcinoma (Urothelial Cancer)—Arlene O. Siefker-Radtke

Brain Tumors—Vivek Subbiah, Michael Pearlman

Glioblastoma/Malignant Gliomas

Other NF-Related Tumors

Medulloblastoma

Meningiomas

Breast Cancer—Senthil Damodaran, Debu Tripathy

ER/PR+

HER2+

Triple-Negative/Basal

Cervical Cancer—Laura L. Holman, Siqing Fu, Shannon N. Westin

Colorectal Cancer—Allan A. L. Pereira, David S. Hong, Goldy C. George, E. Scott Kopetz

Esophageal Cancer (Squamous Cell)—Mustafa Bozkurt, David S. Hong, Goldy C. George, Mariela B. Murphy

Gastric/Gastroesophageal Junction (Adenocarcinoma)—Mustafa Bozkurt, David S. Hong, Goldy C. George, Mariela Blum Murphy

Head and Neck Cancer—Renata Ferrarotto, Kathrina Marcelo-Lewis, Sarina A. Piha-Paul, Sangeeta Goswami, Erminia Massarelli

Salivary Gland

Squamous Cell

Nasopharynx

Kidney (Renal Cell) Cancer—Vivek Subbiah, Nizar M. Tannir

Leukemia—Prajwal C. Boddu, Radhika Kainthla, Tapan M. Kadia, Naveen Pemmaraju

Acute Myeloid Leukemia (AML)

Acute Lymphoblastic Leukemia (ALL)

Chronic Myeloid Leukemia (CML)

Chronic Lymphocytic Leukemia (CLL)

Myeloproliferative Neoplasm (MPN)

Liver Cancer (Hepatocellular)—Shiraj Sen, Xiaochun Liu, Ahmed O. Kaseb

Lung Cancer—Daniel D. Karp, Kathrina Marcelo-Lewis, Ralph G. Zinner, Lauren Byers

NSCLC

SCLC

Lymphoma— Raphael Steiner, Xiaochun Liu, Jason R. Westin

Multiple Myeloma—Hans C. Lee, Manojkumar Bupathi, Jatin J. Shah, Robert Orlowski

Ovarian Cancer—Laura L. Holman, Siqing Fu, Shannon N. Westin

Pancreatic Cancer (Ductal Carcinoma)—Milind Javle, Kathrina Marcelo-Lewis, Goldy C. George, David S. Hong

Prostate Cancer (Adenocarcinoma)—Paul G. Corn, Kathrina Marcelo-Lewis

Sarcoma (Gastrointestinal Stromal Tumors, GIST)—Jason Roszik, Vivek Subbiah, Anthony Conley

Sarcoma

Skin Cancer—Gerald S. Falchook, Scott. Woodman, Michael K. K. Wong

Melanoma—Meredith A. McKean, Gerald S. Falchook, Hussein Tawbi, Scott E. Woodman

Basal Cell—Gerald S. Falchook, Scott E. Woodman, Michael K. K. Wong

Squamous Cell—Gerald S. Falchook, Scott E. Woodman, Michael K. K. Wong

Merkel Cell—Gerald S. Falchook, Scott E. Woodman, Michael K. K. Wong

Testicular Cancer (Germ Cell Carcinoma)—Vivek Subbiah, Lance C. Pagliaro

Thymus Carcinoma (Thymic and Thymoma)—Gerald S. Falchook, Ralph G. Zinner

Thyroid Cancer—Maria E. Cabanillas, Manojkumar Bupathi

Papillary and Follicular Carcinoma

Papillary, Follicular, and Hurthle Cell Carcinoma

Medullary Carcinoma

Anaplastic Carcinoma

Uterine (Endometrial) Cancer—Laura L. Holman, Siqing Fu, Shannon N. Westin

Section 2 Carcinogenesis from the Perspective of Targeted Therapy and Immunotherapy

Section 3 Molecular Targets and Pathways

Signal Transduction–The Big Picture—Daniel D. Karp

Color Key

Angiogenesis—Kathrina Marcelo-Lewis

Angiogenesis Regulators—Kathrina Marcelo-Lewis

Targeting HIF-1α—Kathrina Marcelo-Lewis180

Receptor Tyrosine Kinases—Kathrina Marcelo-Lewis

VEGFR Signaling and Targeting VEGFR —Kathrina Marcelo-Lewis

FGFR Signaling and Targeting FGFR—Kathrina Marcelo-Lewis

Aberrations in FGFR Associated with Cancer—Kathrina Marcelo-Lewis

Targeting the FGFR Pathway—Kathrina Marcelo-Lewis

PDGFR and Targeting PDGFR—Jennifer Herold, Ecaterina Ileana-Dumbrava

TIE Receptors—Ecaterina Ileana-Dumbrava

IGFR-1 and Insulin Receptor— Ashley Perkins, Ecaterina Ileana-Dumbrava

Targeting IGFR-1 and Insulin Receptor—Ashley Perkins, Ecaterina Ileana-Dumbrava

TGFβ/SMAD Pathway—Ashley Perkins, Ecaterina Ileana-Dumbrava

Targeting TGFβ/SMAD Pathway—Ashley Perkins, Ecaterina Ileana-Dumbrava

EGFR Family of Receptors—Kavitha Balaji

EGFR Signaling in Cancer—Kavitha Balaji

EGFR Alterations—Kavitha Balaji

Targeting EGFR—Kavitha Balaji

HER2—Kavitha Balaji

ERBB2/HER2 Alterations in Cancer—Kavitha Balaji

Targeting HER2—Kavitha Balaji

HGF Receptors: MET—Matthew Reilley

Targeting MET—Matthew Reilley

RET Receptor—Matthew Reilley

ALK Receptor—Matthew Reilley

ALK Alterations—Matthew Reilley

KIT—Jennifer Herold

Targeting KIT—Jennifer Herold

ROS-1 Receptor—Matthew Reilley

Targeting ROS-1—Matthew Reilley

G-Protein–Coupled Receptors—Ed Kheder

RAS/MAPK Pathway—Ed Kheder

MAPK Pathway—Ed Kheder

Targeting RAS—Ed Kheder

Targeting BRAF—Ed Kheder

Targeting MEK—Ed Kheder

PI3K Pathway—Ana Stuckett

PI3K–AKT–mTOR Pathway—Ana Stuckett

Targeting PI3K Mutations—Ana Stuckett

Targeting AKT Mutations—Ana Stuckett

Targeting PTEN and TSC Alterations—Ana Stuckett

Targeting mTORC1 and mTORC2—Ana Stuckett

JAK/STAT Pathway—Le Huang

Targeting JAK—Le Huang

Hedgehog Signaling Pathway—Shhyam Moorthy

NOTCH Pathway—Shhyam Moorthy

Wnt Pathway—Shhyam Moorthy

SRC Pathway—Shhyam Moorthy

NFκb Pathway—Shhyam Moorthy

Death Receptors and Apoptosis—Patrick Pilie

Cell Cycle Regulation—Patrick Pilie

TP53—Patrick Pilie

RB1—Patrick Pilie

CDKN2A—Patrick Pilie

DNA Damage Response—Ecaterina Ileana-Dumbrava

Targeting DNA Damage Response—Ecaterina Ileana-Dumbrava

Aurora Kinases—Ecaterina Ileana-Dumbrava

Immunotherapy—Hossein Maymani

Targeting PD-1 and PD-L1—Hossein Maymani

Immunotherapy—Hossein Maymani

Targeting CTLA-4—Hossein Maymani

Immunotherapy—Hossein Maymani

Management of Immune-Related Diarrhea and Colitis—Kathrina Marcelo-Lewis, Ecaterina Ileana-Dumbrava

Management of Immune-Related Hepatitis—Kathrina Marcelo-Lewis, Ecaterina Ileana-Dumbrava

Management of Immune-Related Pneumonitis—Kathrina Marcelo-Lewis, Ecaterina Ileana-Dumbrava

Management of Immune-Related Nephritis—Kathrina Marcelo-Lewis, Ecaterina Ileana-Dumbrava

Management of Immune-Related Skin Rash/Toxicities—Kathrina Marcelo-Lewis, Ecaterina Ileana-Dumbrava

Management of Immune-Related Peripheral Neurologic Toxicities—Kathrina Marcelo-Lewis, Ecaterina Ileana-Dumbrava

Management of Immune-Related Thyroid Function Adverse Events—Kathrina Marcelo-Lewis, Ecaterina Ileana-Dumbrava

Epigenetics—Le Huang

Targeting Epigenetics in Cancer—Le Huang

Antibody–Drug Conjugates—Roman Groisberg

TRK Signaling Pathway—Sandra Montez

Targeting Cancer Metabolism—Shiraj Sen

Ewing Sarcoma Gene Fusion Partners—Daniel D. Karp

Section 4 Targeted and Immunotherapy Agents

Color Key

Abbreviations

Abiraterone Acetate (Zytiga)

Acalabrutinib (Calquence)

Ado-Trastuzumab Emtansine (Kadcyla)

Afatinib Dimaleate (Gilotrif)

Afuresertib

Alectinib (Alecensa)

Alemtuzumab (Campath-1h)

Alisertib

Alpelisib

Apatinib

Atezolizumab (Tecentriq)

Avelumab (Bavencio)

Axicabtagene Ciloleucel (Yescarta)

Axitinib (Inlyta)

Anetumab Ravtansine

AZD-1775

AZD9150

Belinostat (Beleodaq)

Bevacizumab (Avastin)

BI 811283

Bicalutamide (Casodex/Cosudex)

Binimetinib

Blinatumomab (Blincyto)

BMS-936559

Bortezomib (Velcade)

Bosutinib (Bosulif)

Brentuximab Vedotin (Adcetris)

Brigatinib (Alunbrig)

Brivanib Alaninate

Buparlisib

Cabozantinib (Cometriq)

Carfilzomib (Kyprolis)

Cediranib

Ceritinib (Zykadia)

Cetuximab (Erbitux)

Cixutumumab

Cobimetinib (Cotellic)

Combretastatin Disodium

Copanlisib (Aliqopa)

Crizotinib (Xalkori)

Dabrafenib (Tafinlar)

Dacomitinib

Dactolisib

Daratumumab (Darzalex)

Dasatinib (Sprycel)

Denosumab (Xgeva)

Dovitinib

Durvalumab (Imfinzi)

Elotuzumab (Empliciti)

Enasidenib Mesylate (Idhifa)

Encorafenib

Enzalutamide (Xtandi)

Epratuzumab

Erlotinib (Tarceva)

Everolimus (Afinitor)

Farletuzumab

Figitumumab

Foretinib

Fostamatinib Disodium

Galunisertib

Ganitumab

Gefitinib (Iressa)

Gemtuzumab Ozogamicin (Mylotarg)

Idelalisib (Zydelig)

Ibrutinib (Imbruvica)

Imatinib Mesylate (Gleevec)

INC280

Iniparib

Inotuzumab Ozogamicin

Ipilimumab (Yervoy)

Ivosidenib

Lapatinib Ditosylate (Tykerb)

Lenalidomide (Revlimid)

Lenvatinib Mesylate (Lenvima)

LGK974

Linifanib

Linsitinib

Lonafarnib

LOR-253 HCL

Larotrectinib

LOXO-292

LY2157299

Mocetinostat

Mogamulizumab (Poteligeo)

Masitinib Mesylate

Matuzumab

MEDI0639

Midostaurin (Rydapt)

Mirvetuximab Soravtansine

MK-0752

MK-2206

MK-8242

MKC-1

MSC2156119J

Navitoclax

Necitumumab (Portrazza)

Neratinib (Nerlynx)

Nilotinib (Tasigna)

Nimotuzumab

Nintedanib

Niraparib (Zejula)

Nivolumab (Opdivo)

Obinutuzumab (Gazyva)

Ofatumumab (Arzerra)

Olaparib (Lynparza)

Omipalisib

Olaratumab (Lartruvo)

OMP-54F28

Onartuzumab

Orantinib

Osimertinib (Tagrisso)

Pacritinib

Palbociclib (Ibrance)

Panitumumab (Vectibix)

Panobinostat

Pazopanib Hydrochloride (Votrient)

PEG-interferon alfa-2b (Sylatron)

Pembrolizumab (Keytruda)

Pemetrexed (Alimta)

Perifosine

Pertuzumab (Perjeta)

PF-03814735

Pilaralisib

Pimasertib

Pomalidomide (Pomalyst)

Ponatinib Hydrochloride (Iclusig)

Poziotinib

Pralatrexate (Folotyn)

PRI-724

Quizartinib

Ramucirumab (Cyramza)

Refametinib

Regorafenib (Stivarga)

Reolysin

Ridaforolimus

Rigosertib

Rilotumumab

Rituximab (Rituxan)

Romidepsin (Istodax)

Rovalpituzumab Tesirine

Rucaparib Camsylate (Rubraca)

Ruxolitinib Phosphate (Jakafi)

Salirasib

Saracatinib

Selinexor

Selumetinib

Sipuleucel-T (Provenge)

Sirolimus (Rapamune)

Sonidegib (Odomzo)

Sonolisib

Sorafenib (Nexavar)

Sunitinib (Sutent)

Talimogene Laherparepvec (Imlygic)

Talazoparib

Telatinib

Temsirolimus (Torisel)

Teprotumumab

Tipifarnib

Tisagenlecleucel (Kymriah)

Tivantinib

Trabectidin (Yondelis)

Trabedersen

Trametinib (Mekinist)

Trastuzumab (Herceptin)

Tremelimumab

Triciribine

Trebananib

Trifluridine and Tipiracil (Lonsurf)

Valproic Acid (Depakote)

Vandetanib (Caprelsa)

Vantictumab

Vanucizumab

Veliparib

Vemurafenib (Zelboraf)

Venetoclax (Venclexta)

Vismodegib (Erivedge)

Vocimagene Amiretrorepvec

Vorinostat (Zolinza)

Zalutumumab

Ziv-Aflibercept (Zaltrap)

Index

 

 

la

An aparitie	2018
Autor	Daniel D. Karp, Gerald S. Falchook and Joann Lim
Dimensiuni	11.43 x 1.78 x 13.72 cm
Editura	LWW
Format	Softcover
ISBN	9781496389138
Limba	Engleza
Nr pag	408